Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast Foam 0.3% in Hidradenitis Suppurativa
NCT07689188Phase 2Recruiting
- Sponsor
- Harrison Dermatology
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of roflumilast vehicle cream in hidradenitis suppurativa (HS), sponsored by Harrison Dermatology. Primary endpoint: Change from Baseline in Abscess and Inflammatory Nodule Count at 16 weeks. Started Sep 2026; status: recruiting.
02
Drugs
roflumilast vehicle cream
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07689188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689188.